Edgewise Therapeutics, Inc.
EWTX
Clasificación en acciones
#3853
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Precio por acción
$39.75
Capitalización bursátil
$4.28B
Cambio (1 día)
4.83%
Cambio (1 año)
158.29%
País
US
Comercio Edgewise Therapeutics, Inc. (EWTX)
Categoría
Healthcare
Ratio P/B de Edgewise Therapeutics, Inc. (EWTX)
Ratio P/B al October 2026 TTM: 8.90
Según los informes financieros más recientes y el precio de las acciones de Edgewise Therapeutics, Inc., el ratio P/B actual (TTM) es 8.90. Al final de 2023, el ratio P/B era 2.19.
Historial del ratio P/B de Edgewise Therapeutics, Inc. desde 2019 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 8.90 | 65.65% |
| 2024 | 5.37 | 145.74% |
| 2023 | 2.19 | 58.22% |
| 2022 | 1.38 | -49.87% |
| 2021 | 2.76 | -106.24% |
| 2020 | -44.18 | -49.57% |
| 2019 | -87.61 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -29.73% |
US
|
|
| 13.2547 | 49.00% |
US
|
|
| 4.208 | -52.70% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -30.50% |
NL
|
